Reconstitution Guidance

DAXXIFY®
daxibotulinumtoxinA-lanm injection

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Please see Important Safety Information throughout, including BOXED WARNING.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.

Reconstitution

For every 100-Unit DAXXIFY® vial, reconstitute with 1.2 mL of sterile saline*

Dosage



Dose per Site

Inject 0.1 mL into 5 injection points for glabellar lines

Total Dose

40U in 0.5 mL total administered in glabellar lines (0.18 ng of core neurotoxin)

Storage

BEFORE RECONSTITUTION

Store **at room temperature** away from light pre reconstituted (68°F to 77°F).[1]

AFTER RECONSTITUTION

Store **refrigerated** for **up to 72 hours** post reconstitution (36°F to 46°F). ***Do not freeze.***[1]

*Preservative-free

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Please see additional Important Safety Information throughout.

Preparation

1. USE 1.2 ML OF DILUENT

To reconstitute DAXXIFY®, draw up 1.2 mL of sterile saline.[1]*

2. CLEAN STOPPER

Clean the exposed rubber stopper on the DAXXIFY® vial with an alcohol swab.[1]

3. INJECT DILUENT SLOWLY

Slowly inject the saline diluent into the DAXXIFY® vial.[1]

4. MIX THE SOLUTION

Swirl gently to ensure mixing.[1]

5. INSPECT THE SOLUTION

The reconstituted solution should be clear to slightly opalescent, colorless, and free of particulate matter. The reconstituted solution may temporarily appear cloudy. **DO NOT USE** if the solution remains cloudy or discolored or contains flakes or particles.[1]

6. READY FOR TREATMENT

Draw an appropriate dose into a new sterile syringe.

*Preservative-free

DAXXIFY®
daxibotulinumtoxinA-lanm injection

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Please see additional Important Safety Information throughout.

Push Volume by Syringe Type

0.3 ML SYRINGE

1. Draw up 0.5 mL in 2 syringes
   0.3 mL in one syringe and 0.2 mL in another syringe
2. Each tick mark represents 0.01 mL and would contain 0.8U





20U (0.18 ng of core neurotoxin)
BOTOX® COSMETIC
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment[2]



40U (0.18 ng of core neurotoxin)
DAXXIFY®
Reconstituted with 1.2 mL sterile saline† for glabellar lines treatment[1]

0.5 ML SYRINGE

1. Draw up 0.5 mL in a syringe
2. Each tick mark represents 0.01 mL and would contain 0.8U





20U (0.18 ng of core neurotoxin)
BOTOX® COSMETIC
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment[2]



40U (0.18 ng of core neurotoxin)
DAXXIFY®
Reconstituted with 1.2 mL sterile saline† for glabellar lines treatment[1]

1.0 ML SYRINGE

1. Draw up 0.5 mL in a syringe
2. Each tick mark represents 0.02 mL and would contain 1.6U*



20U (0.18 ng of core neurotoxin)
BOTOX® COSMETIC
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment[2]



40U (0.18 ng of core neurotoxin)
DAXXIFY®
Reconstituted with 1.2 mL sterile saline† for glabellar lines treatment[1]

IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agent interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Please see additional Important Safety Information on next page.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products.

*Representation is of common 1.0 mL syringe but some syringes may label barrels differently (ie, 0.01 mL tick marks represent 1U). Please check your syringe tick marks carefully.

†Preservative-free

IMPORTANT SAFETY INFORMATION (continued)

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.
Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide. DAXI-001720.2

DAXXIFY®
daxibotulinumtoxinA-lanm injection

DAXXIFY®
daxibotulinumtoxinA-lanm injection

Contact Medical Information with additional questions

medinfo@revance.com

BOTOX® Cosmetic is a registered trademark of Allergan, Inc.

REFERENCES

1. DAXXIFY® Prescribing Information. Revance Therapeutics, Inc; 2022.
2. BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2020.

REVANCE AESTHETICS

DX00384 DAXI-00739
REVANCEAESTHETICS.COM